Best CBD OIl

Best CBD oil in the U.S.

Study shows hemp compounds prevent coronavirus from entering human cells

Laboratory research is a collaboration of researchers at OHSU, Oregon State University
Study shows hemp compounds prevent coronavirus from entering human cells. Hemp growing in a field amid the dawn.

“The study’s implication is that some hemp-based consumer products have the potential to prevent as well as treat infection from the novel coronavirus,” said senior author Fikadu Tafesse, Ph.D., assistant professor of molecular microbiology and immunology in the OHSU School of Medicine. (Getty Images)

New research reveals compounds in hemp demonstrate an ability to prevent the virus that causes COVID-19 from entering human cells.

The study, published in the Journal of Natural Products, was a collaboration between scientists at Oregon Health & Science University and Oregon State University.

The laboratory study used chemical screening techniques to discover that a pair of distinct cannabinoid acids in hemp — known as cannabigerol acid, or CBGA, and cannabidiolic acid, or CBDA — bind to the SARS-CoV-2 spike protein, blocking a critical step in the process the virus uses to infect people.

Fikadu Tafesse Ph.D. (OHSU), a tall man with dark hair smiling in the Vollum courtyard at OHSU.

Fikadu Tafesse, Ph.D. (OHSU)

“This is a lab study, so it hasn’t been tested clinically,” said senior author Fikadu Tafesse, Ph.D., assistant professor of molecular microbiology and immunology in the OHSU School of Medicine. “However, the study’s implication is that some hemp-based consumer products have the potential to prevent as well as treat infection from the novel coronavirus.”

Known scientifically as Cannabis sativa, hemp is a source of fiber, food, and animal feed. Hemp extracts and compounds are also added to cosmetics, body lotions, and dietary supplements.

The study was led by Richard van Breeman, Ph.D., a researcher with Oregon State’s Global Hemp Innovation Center, College of Pharmacy, and Linus Pauling Institute.

In addition to Tafesse and van Breeman, co-authors include Ruth Muchiri of Oregon State, along with Timothy BatesJules WeinsteinHans Leier, and Scotland Farley of OHSU.

For more information, see the news release from Oregon State University: https://today.oregonstate.edu/news/oregon-state-research-shows-hemp-compounds-prevent-coronavirus-entering-human-cells

 

Article Credits

Affordable, Organic Skincare now available!

You read that right. Affordable, organic skincare that works! Skinly Organics, a women-owned, Wisconsin-made product is sold exclusively where Native Roots Hemp products are sold. See our Locations Page for the nearest location to you. You can always find them at our Native Roots Hemp Hub Stores inside of the Luxemburg Pharmacy, Luxemburg, Wisconsin or at Sweet Willow Wellness in De Pere, WI.  You can shop online here with free shipping or also visit:  www.SkinlyOrganics.com for more information.

What is Skinly Organics? It’s a  full line of affordable skincare that uses unique herbs and blends to support your skin. Whether you’re a pre-teen or a senior, this holistic skincare will leave your skin feeling refreshed, toned and rejuvinated. If you’re prone to acne, our clients who use Skinly Organics have told us they’ve had amazing results in days.

If you have questions, drop us a line.  SkinlyOrganicsChat@gmail.com

Stay healthy. Skinly Organics, SO good for your skin.  SO good for your wallet.

How Hemp/CBD Changed Medicine

Hemp/CBD & Your Health/Wellness

Here at Native Roots Hemp we spend most of our time helping guests better understand the endocannabinoid system and how our organically grown Wisconsin hemp helps the body remain in a more balanced state of being.

But sometimes, others can explain it even better! The article below talks about the Endocannabinoid System and it’s profound effects on the human body.

Hemraj, Dipak. “The Discovery of the Endocannabinoid System: How It’s Changed Medicine.” Cannabis Science, Leafwell.com, April 16, 2018, leafwell.com

It has been written or said in many places, but it is something that needs to be reiterated: had cannabis not become such a maligned plant, Raphael Mechoulam and his team would be awarded the Nobel Prize for the discovery of the endocannabinoid system (ECS). In fact, there are several researchers in the field of endocannoids and phytocannabinoids who would be worthy of such a prize. Thankfully, they have at least been awarded a multitude of other prizes, so we can be assured that there is at least some sense in the world. After all, “If viagra can win the Nobel Prize, why not cannabis?” (Please watch The Scientist to get this reference.)

Endocannabinoid system; ECS; CB1 receptors; CB2 receptors

These scientists have won so many prizes for a good reason; and that reason is because, in discovering the ECS, they’ve changed the way we look at the human body and medicine. Many used to believe that targeting one receptor using one highly purified drug was necessary, but the discovery of the ECS has changed their mind. Nowadays, much of the talk around developing safe pharmaceuticals concerns itself with the ECS and multi-modal treatments. In some cases, learning more about the medical properties of cannabis has made us better doctors.

Indeed, so significant is the discovery of cannabinoids and the endocannabinoid system, that it may help us answer one of life’s most fundamental questions: “How and why are we here?” This is because cannabinoids play a crucial role in the beginnings of life. To quote the Abstract from ‘The endocannabinoid-CB1 receptor system in pre- and postnatal life’:

“Recent research suggests that the endogenous cannabinoids (“endocannabinoids”) and their cannabinoid receptors have a major influence during pre- and postnatal development.

First, high levels of the endocannaboid anandamide and cannabinoid receptors are present in the preimplantation embryo and in the uterus, while a temporary reduction of anandamide levels is essential for embryonal implantation. In women accordingly, an inverse association has been reported between fatty acid amide hydrolase (the anandamide degrading enzyme) in human lymphocytes and miscarriage.

Second, CB1 receptors display a transient presence in white matter areas of the pre- and postnatal nervous system, suggesting a role for CB1 receptors in brain development.

Third, endocannabinoids have been detected in maternal milk and activation of CB1 receptors appears to be critical for milk sucking by newborn mice, apparently activating oral–motor musculature.

Fourth, anandamide has neuroprotectant properties in the developing postnatal brain. Finally, prenatal exposure to the active constituent of marihuana (Δ9-tetrahydrocannabinol) or to anandamide affects prefrontal cortical functions, memory and motor and addictive behaviors, suggesting a role for the endocannabinoid CB1 receptor system in the brain structures which control these functions.

Further observations suggest that children may be less prone to psychoactive side effects of Δ9-tetrahydrocannabinol or endocannabinoids than adults. The medical implications of these novel developments are far reaching and suggest a promising future for cannabinoids in pediatric medicine for conditions including “non-organic failure-to-thrive” and cystic fibrosis.”

Sprouting plant; new life; plant growing.
Picture from https://www.flickr.com/photos/mr_t_in_dc/5057059458; Picture by “Mr.TinDC”.

To break that down for you:

  • The body’s own version of THC, anandamide, is necessary for human life to happen in the first instance.
  • Cannabinoid receptors are necessary for brain development.
  • Endocannabinoids have been discovered in the maternal milk of mice, and there is no reason to believe that other mammals’ milk is not the same.
  • Anandamide protects the brains of newborns.
  • Prenatal exposure to THC or anandamide affects memory, motor and addictive behaviors, and prefrontal cortical functions.

Some theorize that children may actually be less prone to the psychoactive effects of THC! Though there is no definitive evidence behind this, the logic seems to be that, due to the high amounts of anandamide in children, THC may not affect them in the same way it affects adults! This is one more reason given as to why cannabinoids may be an excellent treatment method for children.

However, we are sceptical of this claim, as cannabinoids play a massive role in the development of the brain during childhood and teenage years, and introducing phytocannabinoids without medical supervision during such a sensitive period may cause potential health problems, in particular mental health. There is significant research suggesting that those aged under 25 are actually more sensitive to THC, as their brains are developing. As for CBD, as it is a cannabinoid that does not have any affinity for CB1 or CB2 receptors, it is unlikely to have the effects THC has. Still, we do not know for sure precisely what sort of effect has long-term. CBD still has a physiological effect, after all.

Those who need cannabinoids for a particular health condition, they are still a potentially valid treatment regardless of age. We must also ask ourselves, “Why don’t we treat many other drugs and medications the same way and see what effect they have on the brains of children?” After all, many children are prescribed much harsher drugs than THC when they suffer from serious conditions.

Chemical structure anandamide; anandamide; THC; anandamide THC; skeletal anandamide; endocannabinoid
Anandamide. Picture from: https://commons.wikimedia.org/wiki/File:Anandamide_skeletal.svg

 

 

 

 

 

 

 

 

 

 

 

Now, we don’t know about you, but this sort of thing gets us excited, and we’d be surprised if anyone doesn’t get as excited as we are about such research. Cannabinoids being one of the reasons why life exists? This is the sort of talk that belongs in stoner circles. Yet at least one of those circles must have the spirit of Carl Sagan and other prominent now sadly-passed scientists possessing them, as that talk may just well be true!

Now, not only do cannabinoids seem to have a massive role to play in the beginnings of life, but it may also perform an immensely important part in the continuation of it as well. Cannabinoids are intimately involved in homeostasis – the “checks and balances” that keep the body and its physiological processes in equilibrium. Anandamide is hugely important for maintaining immunological health in the gut. Learning about endocannabinoids and endocannabinoid has given us a greater understanding of immune regulation, and the advances made in cannabinoid pharmacology have given us a whole new range of therapeutic targets. In fact, the ECS has potentially given us an entirely new branch of therapies. The reason why cannabis may be useful for so many conditions is because an “out-of-tune” ECS is implicated in many disease states.

Infinity symbol; cannabis leaves; cannabis; hemp; infinity symbol made from marijuana leaves.
Picture from https://pixabay.com/en/marijuana-drugs-cannabis-drug-hemp-2766323/

That cannabinoids may make up the constituents of life is nothing short of an outstanding discovery. It is almost surprising that we have only just discovered it just over two-and-a-half decades ago. The ECS is so complex that we have barely just begun to scratch the surface on what it does and how we can modulate it. There is still lots more to be done, There is actually lots to be discussed here, and in some ways the way we treat the cannabis plant has asked a some questions that shake some of the philosophical underpinnings of medicine. “How do we ensure the cure isn’t as bad and dangerous as the disease we’re trying to treat?” “Why do we prescribe things that are much worse than cannabis, especially when sometimes the evidence is shaky at best?” “Are there ways we can treat a condition without the need for invasive surgery and/or harsh pharmaceutical drugs?” Who knows? One day, many of the medicines at your local pharmacist may be cannabinoid- and/or terpenoid- based!

What’s the Scoop on Delta-8

How does Delta-8 make you feel?

According to Mercury News:  The effects of Delta8 THC and the traditional Delta-9 THC are fairly similar, but the potency of Delta8 is what sets it apart from its highly psychoactive counterpart. Delta8 can make you feel high, but it is thought to create a milder effect.

When combined with cannabinoids such as CBN (typically reportedly used for anxiety or sleep) the D8 has different effects.  Use it with CBD for a milder euphoric sensation.

And, while we don’t judge, millions of people choose to drink each week throughout America. Many of them suffer hangovers. And, while a high quality plant, such as a hemp plant is thought to lessen the after-effects of an alcohol-induced night out, users of Delta-8 THC report a euphoric feeling without the hangover.

How long will the effects of Delta-8 THC last?

Consumers report effects of Delta-8 can last anywhere from 3 – 8 hours.

Is Delta-8 Legal in Wisconsin?

According to Kush, a substance meeting the definition of “hemp” is legal for purposes of state and federal controlled substances laws regardless of its Delta 8-THC concentration.  This means that any hemp-derived Delta 8 THC that has less than .3% of Delta 9 THC is legal. 

The short answer is “yes.”

4 Things to Know About the FDA’s C BD Guidance

When 2019 began, it was expected to be an incredibly “green” year for the cannabis industry. Canada had just commenced recreational weed sales in October 2018; higher-margin derivative products were expected to hit dispensary shelves in Canada soon thereafter; and President Trump had just signed the farm bill into law, thereby legalizing the industrial production of hemp and hemp-derived cannabidiol (CBD).

Arguably, the greatest excitement surrounded CBD, the nonpsychoactive cannabinoid that’s best known for its perceived medical benefits. Since CBD doesn’t get users high, there’s a considerably broader patient pool for infused products than anything marijuana related. And it also doesn’t hurt that the U.S. population is considerably larger than Canada, providing a juicier opportunity for the CBD industry.

Four vials of cannabinoid-rich liquid lined up on a counter.

IMAGE SOURCE: GETTY IMAGES.

Moreover, with President Trump signing the farm bill into law, it allowed general stores, such as pharmacies and grocers, the opportunity to carry hemp-derived CBD products. In other words, no longer are CBD products carried only in cannabis dispensaries. This more encompassing retail presence should provide a boost to industry sales.

According to the Brightfield Group, U.S. CBD product sales are expected to increase from around a pedestrian $600 million in 2018 to $23.7 billion by 2023. For those of you keeping score at home, this is, indeed, a compound annual growth rate of more than 100% per year over a five-year stretch. This makes CBD a much faster-growing niche than cannabis as a whole.

The FDA lays the hammer down on CBD

And yet, this rapidly growing niche is clouded in worry following a Nov. 25 consumer update from the U.S. Food and Drug Administration (FDA). To quickly summarize the consumer update, the FDA:

  • Noted that CBD has the potential to harm consumers.
  • Pointed out that CBD has the potential to cause side effects that might not immediately be noticed by consumers.
  • Admitted that there are numerous important aspects about CBD that the agency doesn’t know.
A lab researcher in a white coat closely examining a beaker filled with cannabinoid-rich liquid.

IMAGE SOURCE: GW PHARMACEUTICALS.

In particular, the FDA alluded to the only cannabis-derived drug, GW Pharmaceuticals‘ (NASDAQ:GWPH) Epidiolex, as evidence of these bullet points. Despite GW Pharmaceuticals’ lead drug being approved as a treatment for two rare forms of childhood-onset epilepsy in June 2018, Epidiolex was also shown to cause liver injury during clinical studies in some patients. Again, this risk didn’t outweigh the benefits GW Pharmaceuticals’ drug provided in terms of reducing seizure frequency from baseline, but it demonstrates in the eyes of the FDA that CBD doesn’t have a clean bill of health.

This FDA consumer update comes as the agency has been reviewing the compound as an additive to food, beverages, and dietary supplements. The FDA’s findings, based on the update, suggest that the agency is not going to grant companies the ability to add CBD to food, beverages, or dietary supplements at this time. And, as you can imagine, this news wasn’t taken well by Wall Street and investors.

Four things you should know about the FDA’s consumer update on CBD

However, it’s important for investors to understand that this FDA update isn’t as bad as it initially sounds. Here are four important takeaways from the FDA’s CBD guidelines.

1. This move had been telegraphed for months

For starters, the FDA’s consumer update that was critical of CBD’s safety could be seen coming months in advance. Remember, the agency never said it would release concrete guidelines by late summer or early fall. Instead, it only promised to provide an update on the progress it was making in reviewing data and testimony, which it has now done.

Additionally, the FDA hasn’t been shy about cracking down on misleading health claims when it comes to CBD. In July, Curaleaf Holdings (OTC:CURLF), the largest multistate operator in the U.S. by market cap, wound up receiving a warning letter regarding unsubstantiated claims for a variety of CBD products. Even though Curaleaf was quick to respond to these deficiencies, it still wound up costing the company a potentially lucrative distribution deal with CVS Health.

A researcher in a white lab coat making notes on a clipboard in the middle of a hemp farm.
Scroll to top